Victory Capital Management Inc. Sells 1,972 Shares of PetMed Express, Inc. (NASDAQ:PETS)

Victory Capital Management Inc. decreased its holdings in shares of PetMed Express, Inc. (NASDAQ:PETS) by 15.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,881 shares of the company’s stock after selling 1,972 shares during the quarter. Victory Capital Management Inc. owned about 0.05% of PetMed Express worth $150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of PETS. Captrust Financial Advisors raised its holdings in PetMed Express by 72.5% during the 1st quarter. Captrust Financial Advisors now owns 1,570 shares of the company’s stock valued at $41,000 after acquiring an additional 660 shares during the period. Quantbot Technologies LP raised its holdings in PetMed Express by 455.7% during the 2nd quarter. Quantbot Technologies LP now owns 2,206 shares of the company’s stock valued at $43,000 after acquiring an additional 1,809 shares during the period. Point72 Hong Kong Ltd raised its holdings in PetMed Express by 2,023.8% during the 2nd quarter. Point72 Hong Kong Ltd now owns 3,122 shares of the company’s stock valued at $62,000 after acquiring an additional 2,975 shares during the period. Tower Research Capital LLC TRC raised its holdings in PetMed Express by 633.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,839 shares of the company’s stock valued at $79,000 after acquiring an additional 4,179 shares during the period. Finally, Barclays PLC raised its holdings in PetMed Express by 533.3% during the 4th quarter. Barclays PLC now owns 5,421 shares of the company’s stock valued at $95,000 after acquiring an additional 4,565 shares during the period. Institutional investors own 74.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Morgan Stanley lowered their target price on shares of PetMed Express from $10.00 to $7.00 and set an “underweight” rating on the stock in a report on Tuesday, October 31st. StockNews.com assumed coverage on shares of PetMed Express in a research report on Thursday, October 5th. They set a “hold” rating for the company. Finally, TheStreet lowered shares of PetMed Express from a “c-” rating to a “d+” rating in a research report on Wednesday.

PetMed Express Price Performance

PETS opened at $7.21 on Monday. The company has a fifty day moving average price of $10.26 and a 200-day moving average price of $12.74. The firm has a market capitalization of $152.49 million, a P/E ratio of -24.86 and a beta of 0.70. PetMed Express, Inc. has a one year low of $5.50 and a one year high of $22.64.

PetMed Express (NASDAQ:PETS) last announced its earnings results on Monday, October 30th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.09). PetMed Express had a positive return on equity of 0.93% and a negative net margin of 2.25%. The company had revenue of $71.00 million during the quarter, compared to analysts’ expectations of $77.13 million. During the same quarter last year, the firm posted $0.13 earnings per share. On average, analysts expect that PetMed Express, Inc. will post 0.16 earnings per share for the current year.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.